Objective
to investigate the clinical efficacy of ticagrelor vs placebo in addition to aspirin in stable CAD patients with type 2 diabetes and history of previous PCI
Study
prespecified subgroup analysis of the THEMIS trial which is a phase 3, double-blinded, multicentre randomised trial (58% of overall THEMIS)
Population
patients with history of PCI and DM type 2 and previous PCI: median time since recent PCI 3.3 years
Endpoints
composite cardiovascular death, MI or stroke during median follow-up 3.3 years
Conclusion
ticagrelor treatment in patients with diabetes, stable CAD and previous PCI reduced cardiovascular death, myocardial and stroke compared with placebo, but this was associated with increased bleeding
Bhatt et al. Lancet. 2019;394:1118-20
